129 related articles for article (PubMed ID: 7519381)
1. Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer.
Sands ME; Zagars GK; Pollack A; von Eschenbach AC
Urology; 1994 Aug; 44(2):215-20. PubMed ID: 7519381
[TBL] [Abstract][Full Text] [Related]
2. The staging pelvic lymphadenectomy: implications as an adjunctive procedure for clinically localized prostate cancer.
Alagiri M; Colton MD; Seidmon EJ; Greenberg RE; Hanno PM
Br J Urol; 1997 Aug; 80(2):243-6. PubMed ID: 9284196
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
4. Preoperative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: implications for the choice of primary treatment.
Ennis RD; Flynn SD; Fischer DB; Peschel RE
Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):317-22. PubMed ID: 7523342
[TBL] [Abstract][Full Text] [Related]
5. Risk of nodal metastases at laparoscopic pelvic lymphadenectomy using PSA, Gleason score, and clinical stage in men with localized prostate cancer.
Hoenig DM; Chi S; Porter C; Tackett L; Smith DS; Cohen SI; Stein BS
J Endourol; 1997 Aug; 11(4):263-5. PubMed ID: 9376845
[TBL] [Abstract][Full Text] [Related]
6. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
7. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate.
Stone NN; Stock RG; Parikh D; Yeghiayan P; Unger P
J Urol; 1998 Nov; 160(5):1722-6. PubMed ID: 9783940
[TBL] [Abstract][Full Text] [Related]
8. Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer.
Narayan P; Fournier G; Gajendran V; Leidich R; Lo R; Wolf JS; Jacob G; Nicolaisen G; Palmer K; Freiha F
Urology; 1994 Oct; 44(4):519-24. PubMed ID: 7524237
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
Spencer JA; Chng WJ; Hudson E; Boon AP; Whelan P
Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906
[TBL] [Abstract][Full Text] [Related]
10. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
Blackwell KL; Bostwick DG; Myers RP; Zincke H; Oesterling JE
J Urol; 1994 Jun; 151(6):1565-70. PubMed ID: 7514689
[TBL] [Abstract][Full Text] [Related]
11. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
[TBL] [Abstract][Full Text] [Related]
12. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
13. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy.
D'Amico AV; Renshaw AA; Schultz D; Rocha S; Richie JP
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):847-51. PubMed ID: 10571188
[TBL] [Abstract][Full Text] [Related]
14. Laparoscopic lymph node sampling in locally advanced prostate cancer.
Parkin J; Keeley FX; Timoney AG
BJU Int; 2002 Jan; 89(1):14-7; discussion 17-8. PubMed ID: 11849153
[TBL] [Abstract][Full Text] [Related]
15. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
16. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan.
Ishizuka O; Tanabe T; Nakayama T; Kawakami M; Kinebuchi Y; Nishizawa O
Int J Urol; 2005 Aug; 12(8):728-32. PubMed ID: 16174046
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer.
Zagars GK; Pollack A; Kavadi VS; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 May; 32(2):293-306. PubMed ID: 7538498
[TBL] [Abstract][Full Text] [Related]
19. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
20. Serum prostate-specific antigen and the biologic progression of prostate cancer.
Kabalin JN; McNeal JE; Johnstone IM; Stamey TA
Urology; 1995 Jul; 46(1):65-70. PubMed ID: 7541589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
